Respiratory Disease Vaccine Market Research Report by Infection (Influenza Virus, Pertussis, and Streptococcus Pneumoniae), by Type (Bacterial Vaccine, Combination Vaccine, and Viral Vaccine), by Age Group, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19
The Global Respiratory Disease Vaccine Market size was estimated at USD 19.92 Billion in 2020 and expected to reach USD 20.98 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 5.67% from 2020 to 2026 to reach USD 27.75 Billion by 2026.
Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Market Segmentation & Coverage: This research report categorizes the Respiratory Disease Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Infection, the Respiratory Disease Vaccine Market was studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
Based on Type, the Respiratory Disease Vaccine Market was studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
Based on Age Group, the Respiratory Disease Vaccine Market was studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
Based on Geography, the Respiratory Disease Vaccine Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Respiratory Disease Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles: The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Respiratory Disease Vaccine Market, including AstraZeneca, Bavarian Nordic, Bayer AG, Bio Farma, Dynavax Technologies Corporation, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., and Serum institute of India Private Limited.
The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as: 1. What is the market size and forecast of the Global Respiratory Disease Vaccine Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Disease Vaccine Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Disease Vaccine Market? 4. What is the competitive strategic window for opportunities in the Global Respiratory Disease Vaccine Market? 5. What are the technology trends and regulatory frameworks in the Global Respiratory Disease Vaccine Market? 6. What is the market share of the leading vendors in the Global Respiratory Disease Vaccine Market? 7. What modes and strategic moves are considered suitable for entering the Global Respiratory Disease Vaccine Market?
Our reports have been used by over 10K customers, including:
Executive Summary The mRNA technology finds its applications in many diseases including the Covid-19 vaccine. The market for mRNA is mostly driven by the Covid-19 vaccine besides its major usage in cancer therapies. With the mutation of the coronavirus and possible spread of variants of the virus, the mRNA companies are...
This study ’s Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants.
Emphysema (Respiratory) - Drugs in Development, 2021 Summary Emphysema (Respiratory) - Drugs in Development, 2021 provides an overview of the Emphysema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Emphysema, complete with analysis...
“Adenovirus infections – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenovirus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
Inhaled Nitric Oxide Market by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027 The global inhaled nitric oxide market was valued at $634.4 million in 2019 and...
Acute Inflammation (Immunology) - Drugs in Development, 2021 Summary Acute Inflammation (Immunology) - Drugs in Development, 2021 provides an overview of the Acute Inflammation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute...
Articular Cartilage Defect (Musculoskeletal) - Drugs in Development, 2021 Summary Articular Cartilage Defect (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Articular Cartilage Defect pipeline landscape. The report provides comprehensive information on the therapeutics...
Choroidal Neovascularization (Ophthalmology) - Drugs in Development, 2021 Summary Choroidal Neovascularization (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Choroidal Neovascularization pipeline landscape. The report provides comprehensive information on the therapeutics...
Gastric Motility Disorder (Gastrointestinal) - Drugs in Development, 2021 Summary Gastric Motility Disorder (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Gastric Motility Disorder pipeline landscape. The report provides comprehensive information on the therapeutics...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.